Claims for Patent: 9,345,770

Summary for Patent: 9,345,770

Title:	Immunogenic tumor associated stromal cell antigen peptides and methods of their use
Abstract:	Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed.
Inventor(s):	Storkus; Walter J. (Pittsburgh, PA), Bose; Anamika (Kolkata, IN), Taylor; Jennifer Lynn (McDonald, PA), Zhao; Xi (Pittsburgh, PA), Lowe; Devin B. (Pittsburgh, PA)
Assignee:	University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:	14/358,705
Patent Claims:	1. A method for eliciting an immune response to a tumor in a subject, comprising administering to a subject a therapeutically effective amount of a composition comprising a plurality of polypeptides, wherein each polypeptide in the plurality is at most twelve amino acids in length, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a leucine (L) or a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L) or a valine (V), thereby eliciting the immune response to the tumor in the subject, wherein the tumor expresses DLK1, NRP1 and TEM1. 2. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of dasatinib, bevacizumab, sunitinib, axitinib, an HSP90 inhibitor, or gemcitabine/fludarabine. 3. The method of claim 1, wherein the immune response decreases growth of the tumor in the subject. 4. The method of claim 1, wherein the immune response decreases vascularization of the tumor. 5. The method of claim 1, wherein the tumor is a colorectal cancer. 6. The method of claim 1, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L). 7. The method of claim 1, wherein the cancer is a lung cancer. 8. A method for inhibiting the growth of a cancer, the method comprising culturing cytotoxic T lymphocytes (CTLs) or CTL precursor cells with a composition and an antigen presenting cell in vitro to produce activated CTLs or CTL matured from the CTL precursors that recognize tumor associated stromal cell antigens, wherein the composition comprises a plurality of polypeptides, wherein each polypeptide in the plurality is at most twelve amino acids in length, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a leucine (L) or a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L) or a valine (V); and contacting the cancer, with the activated CTLs or CTLs matured from the CTL precursors, wherein the cancer expresses DLK1, NRP1 and TEM1, thereby inhibiting the growth of the cancer. 9. The method of claim 8, wherein the cancer is a colorectal cancer. 10. The method of claim 8, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L). 11. The method of claim 8, wherein the cancer is lung cancer. 12. A method for eliciting an immune response to a tumor in a subject, comprising administering to a subject a therapeutically effective amount of a composition comprising a plurality of polypeptides, wherein each polypeptide in the plurality is at most twelve amino acids in length, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a leucine (L) or a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L) or a valine (V), wherein the tumor expresses DLK1, NRP1 and TEM1 and wherein the tumor is a melanoma, thereby eliciting the immune response to the tumor. 13. The method of claim 12, wherein the melanoma is a superficial spreading melanoma, a nodular melanoma, an acral lentiginous melanoma, a lentigo maligna, a clear cell sarcoma, a mucosal melanoma or a uveal melanoma. 14. The method of claim 12, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L). 15. The method of claim 14, further comprising administering to the subject a therapeutically effective amount of dasatinib. 16. A method for inhibiting the growth of a cancer cell, the method comprising culturing cytotoxic T lymphocytes (CTLs) or CTL precursor cells with a composition and an antigen presenting cell in vitro to produce activated CTLs or CTL matured from the CTL precursors that recognize tumor associated stromal cell antigens, wherein the composition comprises a plurality of polypeptides, wherein each polypeptide in the plurality is at most twelve amino acids in length, wherein the plurality of polypeptides comprises: (a) a Protein Delta Homolog 1 (DLK1) polypeptide comprising the amino acid sequence set forth as ILGVLTSLV (SEQ ID NO: 2); (b) a Neuropilin 1 (NRP1) polypeptide comprising the amino acid sequence set forth as GX.sub.4LGMVSGL (SEQ ID NO: 7), wherein X.sub.4 is a leucine (L) or a methionine (M); and (c) a Tumor Endothelial Marker 1 (TEM1) polypeptide comprising the amino acid sequence set forth as LLVPTCVFX.sub.5V (SEQ ID NO: 9), wherein X.sub.5 is a leucine (L) or a valine (V); and contacting the cancer, with the activated CTLs or CTLs matured from the CTL precursors, thereby inhibiting the growth of the cancer, wherein the cancer expresses DLK1, NRP1 and TEM1 and is a melanoma. 17. The method of claim 16, wherein the melanoma is a superficial spreading melanoma, a nodular melanoma, an acral lentiginous melanoma, a lentigo maligna, a clear cell sarcoma, a mucosal melanoma or a uveal melanoma.

Details for Patent 9,345,770

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-11-16